satigrel has been researched along with thromboxane a2 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iida, N | 1 |
| Harada, K; Kobayashi, S; Nagakura, N; Saeki, T; Saito, I; Yamanaka, T; Yoshitake, S | 1 |
2 other study(ies) available for satigrel and thromboxane a2
| Article | Year |
|---|---|
[Inhibitor of thromboxane A2 synthesis as anticoagulant in hemodialysis].
Topics: Animals; Aspirin; Blood Coagulation Disorders; Cyclooxygenase Inhibitors; Dogs; Fatty Acids, Monounsaturated; Humans; Methacrylates; Phospholipases; Receptors, Prostaglandin; Receptors, Thromboxane; Renal Dialysis; Sulfinpyrazone; Thromboxane A2; Thromboxane-A Synthase | 1991 |
Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Topics: Blood Platelets; Cilostazol; Cyclic AMP; Cyclic GMP; Cyclooxygenase Inhibitors; Fatty Acids, Monounsaturated; Humans; In Vitro Techniques; Isoenzymes; Male; Papaverine; Phosphodiesterase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Tetrazoles; Thromboxane A2 | 1996 |